Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine as Conversion Therapy of Locally Advanced Colorectal Cancer
Conditions: Colorectal Cancer Interventions: Drug: Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2024 Category: Research Source Type: clinical trials
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Conditions: Nanoliposomal Irinotecan; Cadonilimab; Oxaliplatin; Capecitabine; First-Line; Advanced Cancer; Pancreatic Adenocarcinoma; Drug Use Interventions: Drug: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2024 Category: Research Source Type: clinical trials
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR
Conditions: Triple-Negative Breast Cancer Interventions: Biological: Pembrolizumab; Biological: sac-TMT; Drug: Capecitabine Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2024 Category: Research Source Type: clinical trials
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
Conditions: RECTAL NEOPLASMS; Rectal Cancer Interventions: Radiation: Radiotherapy; Drug: Tislelizumab; Drug: Capecitabine; Drug: Oxaliplatin; Drug: Capecitabine Sponsors: Fudan University; Shanghai Zhongshan Hospital; Shanghai Changzheng Hospital; Huadong Hospital; RenJi Hospital; The Fourth Hospital of Hebei Medical University; First Hospital of China Medical University; Liaoning Cancer Hospital& Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials
Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer
Conditions: Pancreatic Cancer Non-resectable Interventions: Drug: Huaier Granule; Drug: Capecitabine Sponsors: Health Science Center of Xi ' an Jiaotong University; LinkDoc Technology (Beijing) Co. Ltd.; Huazhong University of Science and Technology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
Conditions: Triple Negative Breast Neoplasms Interventions: Drug: UTD1 Sponsors: Hunan Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2024 Category: Research Source Type: clinical trials
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Conditions: Metastatic Breast Cancer Interventions: Drug: ESG401; Drug: Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician ' s Choice) Sponsors: Shanghai Escugen Biotechnology Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Conditions: Triple-Negative Breast Cancer Interventions: Drug: BL-B01D1; Drug: Eribulin; Drug: Vinorelbine; Drug: Gemcitabine; Drug: Capecitabine Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
Conditions: Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis Interventions: Drug: Neratinib maleate in combination with capecitabine Sponsors: Convalife (Shanghai) Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
Conditions: Breast Cancer Interventions: Drug: cyclophosphamide , methotrexate , vinorelbine ,capecitabine Sponsors: Sun Yat-sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer Interventions: Drug: Zumsemetinib; Drug: Capecitabine; Drug: Zoledronic acid; Drug: Denosumab Sponsors: Washington University School of Medicine; United States Department of Defense; Aclaris Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
Conditions: Colon Cancer Interventions: Drug: Serplulimab; Drug: Capecitabine; Drug: Oxaliplatin Sponsors: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
Conditions: Triple-negative Breast Cancer Interventions: Drug: Inosine; Drug: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Conditions: Triple-negative Breast Cancer Interventions: Drug: Quercetin; Drug: Dasatinib; Drug: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Conditions: Gastroesophageal Junction Adenocarcinoma; Liver Cancer Stage IV; Biliary Tract Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Gastric Cancer Interventions: Radiation: Hypofractionated radiotherapy/SBRT （5-8 Gy/fx，3-5 fx）; Drug: Anti-PD-1 monoclonal antibody; Drug: Oxaliplatin and Capecitabine; Drug: Anti-VEGF 15mg/kg; Drug: Anti-VEGF 7.5mg/kg; Drug: Gemcitabine and Cisplatin; Drug: Gemcitabine and Albumin paclitaxel Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
